Tenax Therapeutics TENX 深 滬
等待開盤 09-17 09:30:00 美东时间
1.82
-0.010
-0.55%
華盛通- 最 高1.93
- 今 開1.88
- 成交量 226.22万股
- 最 低 1.815
- 昨 收 1.83
- 總市值 6811.15万
- 52周最高 19.40
- 市盈率 靜 --
- 換手率 6.04%
- 52周最低 1.31
- 委 比 90.53%
- 總股本 3742.39万
- 歷史最高 274560.00
- 量 比 0.57
- 振 幅 6.28%
- 歷史最低 1.31
- 每 手 1
- 風險率 4.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Downgrades Tenax Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral.
08-31 20:55
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
<p>Tenax Therapeutics announced positive results from the Phase 3 LEVEL trial of TNX-103 for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). In patients with baseline 6MWD below 333 meters, TNX-103 showed a 26.3-meter improvement in 6MWD, a 47% reduction in NT-proBNP, and a 4.9 mmHg reduction in RVSP compared to placebo. These findings suggest TNX-103 may provide clinical benefits for PH-HFpEF patients, pa...
08-29 12:21
Tenax rises on over $1.8M insider buying
Cardiopulmonary drug developer Tenax Therapeutics (TENX) added nearly 13% in the premarket trading on Tuesday after Adar1 Capital Management, one of its key shareholders, bought more than $1.8M worth ...
08-25 19:36
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
08-12 00:02
Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 resulted in a 49% greater reduction in NT-proBNP compared to placebo (nominal p<0...
08-10 19:07
Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 29.63 percent decrease over losses of $(0.27) per share from the same period last year.
07-31 19:30
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics reported Q2 2026 financial results with $118M cash, increased R&D expenses to $12.9M, and a net loss of $17.8M. The company expects Phase 3 LEVEL trial top-line data in August 2026 and plans to present results at the ESC Congress. Enrollment for the LEVEL-2 trial is ongoing, targeting completion by end-2027. Levosimendan (TNX-103) is being evaluated for pulmonary hypertension associated with heart failure.
07-31 11:00
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
